How tumor-infiltrating neutrophils affect breast cancer treatment
Immunosuppression and Metabolic Rewiring in Tumor-infiltrating Neutrophils
['FUNDING_R01'] · UNIVERSITY OF NOTRE DAME · NIH-11079460
This study is looking at how certain immune cells called neutrophils in metastatic breast cancer might make it harder for treatments to work, and it hopes to find ways to target these cells to improve therapy outcomes for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NOTRE DAME (nih funded) |
| Locations | 1 site (NOTRE DAME, UNITED STATES) |
| Trial ID | NIH-11079460 on ClinicalTrials.gov |
What this research studies
This research investigates the role of tumor-infiltrating neutrophils (TINs) in metastatic breast cancer and their contribution to resistance against immunotherapy. By utilizing advanced techniques like single-cell RNA sequencing, the study aims to understand how these neutrophils survive in the tumor microenvironment and how they can be targeted to improve treatment outcomes. The focus is on a specific enzyme, Acod1, which is believed to play a crucial role in the immunosuppressive functions of TINs. If successful, this research could lead to new strategies that enhance the effectiveness of existing cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic breast cancer who are currently resistant to standard immunotherapy treatments.
Not a fit: Patients with early-stage breast cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy responses for patients with metastatic breast cancer.
How similar studies have performed: Other research has shown promising results in targeting immune cells to enhance cancer treatment, suggesting that this approach may also yield significant benefits.
Where this research is happening
NOTRE DAME, UNITED STATES
- UNIVERSITY OF NOTRE DAME — NOTRE DAME, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LU, XIN — UNIVERSITY OF NOTRE DAME
- Study coordinator: LU, XIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy